MDGL
NASDAQMadrigal Pharmaceuticals Inc.
Price$518.52-12.12 (-2.28%)
01:30 PM07:45 PM
News · 26 weeks64-73%
2025-10-262026-04-19
Mix3190d
- Insider12(39%)
- Other12(39%)
- SEC Filings4(13%)
- Analyst1(3%)
- Leadership1(3%)
- Earnings1(3%)
Latest news
25 items- PRMadrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026CONSHOHOCKEN, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two hou
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 12 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 15, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggre
- INSIDEREVP and CFO Dier Mardi was granted 5,215 shares and sold $853,993 worth of shares (1,982 units at $430.87), increasing direct ownership by 35% to 12,490 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERPresident and CEO Sibold William John was granted 14,995 shares and sold $718,316 worth of shares (1,663 units at $431.94), increasing direct ownership by 9% to 161,829 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERGeneral Counsel Kelley Shannon T was granted 4,017 shares and sold $155,498 worth of shares (360 units at $431.94), increasing direct ownership by 43% to 12,138 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECSEC Form 144 filed by Madrigal Pharmaceuticals Inc.144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- INSIDERChief Commercial Officer Huntsman Carole was granted 3,989 shares and sold $180,983 worth of shares (419 units at $431.94), increasing direct ownership by 39% to 12,692 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Taub Rebecca sold $212,083 worth of shares (491 units at $431.94), decreasing direct ownership by 0.11% to 452,213 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERChief Medical Officer Soergel David was granted 4,374 shares, increasing direct ownership by 58% to 11,919 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on March 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate
- INSIDEREVP and CFO Dier Mardi sold $505,389 worth of shares (1,183 units at $427.21), decreasing direct ownership by 11% to 9,257 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Levy Richard S exercised 2,500 shares at a strike of $7.36, increasing direct ownership by 10% to 27,697 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceCONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medicatio
- SECSEC Form 10-K filed by Madrigal Pharmaceuticals Inc.10-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial ResultsFourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of developmentReports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggr
- PRRibo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASHSUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm
- PRMadrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA ProgramsCompany advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatmentMadrigal will develop next-generation siRNA therapies that silence genes implicated in MASH CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure) for six p
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 1, 2026 to 21 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggrega
- PRMadrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approx